Compare Grab Holdings Ltd. (GRAB) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Grab Holdings Ltd. trades at $3.18 (market cap $12.72B), while Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B). The key difference: Grab Holdings Ltd. and Halozyme Therapeutics Inc. Common Stock are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GRAB | HALO | |
|---|---|---|
Market Cap | $12.72B | $12.58B |
Volume | 65,352,859 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $6.17 | $115.22 |
52-Week Low | $2.80 | $61.63 |
Typical Hold Time | 94 Days | 1 Days |
Enterprise Value | $8.46B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Grab Holdings (GRAB) trades at $3.195, up 3.73% today, showing strong momentum after recent volatility. The stock demonstrates improving fundamentals with revenue growing from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Recent Q2 2026 earnings beat expectations with $0.06 EPS versus $0.05 expected, while technical indicators show bearish signals despite neutral oscillators. The company's $1.49B acquisition of Atome Financial positions it for financial services expansion.
Grab presents a compelling turnaround story with accelerating revenue growth and recent profitability. The strong analyst consensus (91.67% buy ratings) and $30M CEO share purchase signal confidence, though technical weakness and competitive pressures in Southeast Asia's ride-hailing market warrant caution. Key catalysts include continued execution on profitability targets and successful integration of Atome acquisition.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
